At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 884 enrolled
Drug / intervention
Insulin Glargine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
In Brief
A Phase 3 clinical trial evaluating Insulin Glargine, LY2189265, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 884 participants across 101 sites in 16 countries.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of LY2189265 in comparison to Insulin Glargine, both in combination with Insulin Lispro (plus or minus Metformin), in participants with Type 2 Diabetes treated with 1 or 2 injections of insulin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesArgentina, Australia, Belgium, Brazil, Canada, Denmark, Greece, Hungary, Mexico, Poland, Puerto Rico, Russia, Spain, Sweden, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartNov 2010
Primary CompletionFeb 2012
Study CompletionSep 2012
TodayJul 2026
First PostedAug 30, 2010
Enrollment StartNov 1, 2010
Primary CompletionFeb 1, 2012
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.8 years ago
Interventions
Insulin Glarginedrug
LY2189265drug
Insulin Lisprodrug